+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
O

Actively Recruiting

Crohns disease is a chronic inflammatory condition affecting the digestive tract and is currently incurable. This research aims to evaluate how safe and effective the drug upadacitinib is for treating moderately to severely active Crohns disease in real-world settings. The study will monitor any adverse events and track changes in disease activity among participants. All participants will receive upadacitinib as prescribed by their own doctors according to approved local guidelines. The study plans to enroll about 240 participants in Japan who have recently started upadacitinib treatment. Treatment will follow routine clinical practice without altering the prescribed approach. Participants will be followed for up to 64 weeks with visits that may occur in person or virtually, aligned with standard care. Researchers will assess outcomes such as the percentage of participants experiencing serious infections related to the drug. There is expected to be no extra burden beyond usual medical care throughout the study period.

Age: 15Years +All Genders
104 locations
S

Actively Recruiting

Researchers are investigating the best way to assess the severity of intermediate narrowing in the left main coronary artery, which is linked to poor outcomes. The study compares three methods optical coherence tomography OCT derived minimal lumen area MLA, invasive fractional flow reserve FFR, and noninvasive computed tomography angiography-based FFR FFRCT. This research aims to find the optimal OCT-MLA cut-off and evaluate FFRCTs diagnostic accuracy against FFR as the reference standard. Participants undergo a multimodality assessment including OCT, invasive FFR, coronary computed tomography angiography CTA, and FFRCT. OCT is a newer imaging technique with higher resolution than IVUS, while FFR measures blood flow impact on lesions invasively. FFRCT uses computational fluid dynamics to predict blood flow noninvasively from CTA images. The study compares these methods specifically for intermediate left main stenosis to determine their accuracy and usefulness. During the procedure visit, participants receive OCT, FFR, CTA, and FFRCT assessments to measure coronary artery narrowing and blood flow. Researchers collect multiple measurements and compare the results. Clinical outcomes are also followed for one year. This includes monitoring symptoms, imaging, and other clinical endpoints to evaluate the diagnostic methods predictive value and safety. The total participation timeline includes baseline procedure assessments and a one-year follow-up period.

Age: 18Years +All GendersPhase Not Applicable
13 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
L

Actively Recruiting

Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.

All AgesAll Genders
338 locations
M

Actively Recruiting

This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.

All AgesAll Genders
402 locations
R

Actively Recruiting

Researchers are evaluating pumitamig BNT327 combined with chemotherapy etoposidecarboplatin compared to atezolizumab combined with the same chemotherapy for participants with previously untreated extensive-stage small-cell lung cancer. This Phase III, multisite, randomized, double-blinded study aims to compare these treatments to better understand options for first-line ES-SCLC therapy. The study has two stages involving different treatment arms. Stage 1 includes two pumitamig doses combined with chemotherapy and one control arm with atezolizumab plus chemotherapy. Stage 2 has one pumitamig dose treatment arm and a control arm with atezolizumab plus chemotherapy. Participants receive intravenous infusions of study drugs, with the option to switch from carboplatin to cisplatin if needed. Each stage has a screening period up to 21 days, followed by induction and maintenance treatment until disease progression, intolerable side effects, withdrawal, study end, or up to 2 years, then a safety and survival follow-up period. Participants undergo screening to confirm eligibility, then receive treatments according to randomization. Assessments include survival, progression-free survival, response rates, duration of response, and quality of life measured through questionnaires. Safety monitoring tracks adverse events and treatment delays or discontinuations. Follow-up includes safety visits and survival tracking, with total participation lasting up to approximately 46 months from start. The study is designed to monitor long-term outcomes and tolerability of these combinations in ES-SCLC treatment.

Age: 18Years +All GendersPhase 3
225 locations
G

Actively Recruiting

Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.

Age: 18Years +All GendersPhase 2Phase 3
366 locations